RFL Insider Trading
Insider Ownership Percentage: 10.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Rafael Share Price & Price History
Current Price: $1.67
Price Change: ▲ Price Increase of +0.07 (4.38%)
As of 04/17/2025 04:58 PM ET
Rafael Insider Trading History
Rafael Institutional Trading History
Data available starting January 2016
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Read More on Rafael
Volume
42,587 shs
Average Volume
31,763 shs
Market Capitalization
$41.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
Who are the major institutional investors of Rafael?
Which major investors are buying Rafael stock?
During the last quarter, RFL stock was purchased by institutional investors including:
- Wealth Enhancement Advisory Services LLC